首页> 外文期刊>Advances in Nephrology >Incremental Hemodialysis Schedule in Patients with Higher Residual Renal Function at the Start of Dialysis
【24h】

Incremental Hemodialysis Schedule in Patients with Higher Residual Renal Function at the Start of Dialysis

机译:透析开始时残余肾功能较高的患者的递增血液透析时间表

获取原文
       

摘要

We present an observational study to evaluate a progressive schedule of dose of dialysis, starting with 2 HD/week, when the renal clearance of urea was equal to or greater than 2,5 mL/min/1,73 m2and the patient is in a stable clinical situation. From 2006 to 2011, 182 patients started hemodialysis in our center, of which 134 were included in the study. Residual renal function (RRF), Kt/V, eKru, nPCR, hemoglobin, weekly erythropoietin dose, and beta-2-microglobulin were determined at 6, 12, 18, 24, and 30 months after dialysis initiation. Seventy patients (52%) began with the progressive schedule of 2 HD/week and 64 (48%) patients began with the conventional thrice-weekly schedule (3 HD/week). The decline of RRF was lower in the group of 2 HD/week: 0,20 (0,02–0,53) versus 0,50 (0,14–1,08) mL/min/month (median and interquartile range,P=0,009). No relationship was found between the decline rate and the basal RRF. Survival analysis did not show differences between both groups. Our experience demonstrates that patients with higher residual renal function may require less than conventional 3 HD sessions per week at the start of dialysis. Twice-weekly hemodialysis schedule is safe and cost-effective and may have additional benefit in maintaining the residual renal function.
机译:我们进行一项观察性研究,以评估从2 HD /周开始的逐步剂量方案,即当尿素的肾脏清除率等于或大于2,5μmL/ min / 1,73μm2并且患者处于临床情况稳定。从2006年到2011年,我们中心有182例患者开始了血液透析,其中134例被纳入研究。在透析开始后的6、12、18、24和30个月测定残余肾功能(RRF),Kt / V,eKru,nPCR,血红蛋白,每周促红细胞生成素剂量和β-2-微球蛋白。七十名患者(52%)以2 HD /周的进展时间表开始,而64例(48%)患者以常规的三周/周(3 HD /周)开始。在2个HD /周组中,RRF的下降较低:0.2(0.2-0.53)/0.5(0.14-10.88)mL / min /月/月(中位数和四分位数范围) ,P = 0,009)。下降率与基础RRF之间没有关系。生存分析未显示两组之间的差异。我们的经验表明,具有较高残余肾功能的患者在透析开始时每周可能需要少于常规3次HD疗程。每周两次的血液透析时间表是安全且具有成本效益的,并且在保持残余肾功能方面可能还有其他好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号